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CONTINUOUS RENAL REPLACEMENT THERAPY
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SUMMARY - Acute renal failure (ARF) is currently more frequently seen as part of a more complex
syndrome defined by sepsis and/or multiple organ failure. Evolution in the field of hemodialysis has led
to a parallel development of new systems for continuous renal replacement therapy (CRRT) in criti-
cally ill patients. The various CRRT modalities differ in the type of vascular access, application of dif-
fusive or convective clearance (or a combination of both), and location where the replacement fluid
enters the circuit. CRRTs have certainly facilitated the management of critically ill patients with ARF
combined with cardiovascular instability, severe fluid overload, hypercatabolism, cerebral edema, adult
respiratory distress syndrome, lactic acidosis, sepsis or other inflammatory syndromes, crush syndrome,
congestive heart failure, and cardiopulmonary bypass. Continuous therapies incorporate several advan-
tages including improved hemodynamic stability, optimal fluid balance, gradual urea removal, elimina-
tion of septic mediators, and the possibility of unlimited parenteral nutrition. Major difficulties and
unsolved problems of CRRT are the ongoing necessity for continuous anticoagulation, considerable
loss of amino acids, vitamins, trace elements, potassium, phosphate, and some drugs as well as immo-
bilization of the patient. The advantages of CRRT should theoretically translate into improved out-
comes of critically ill ARF patients, but the superiority of continuous modalities in terms of outcomes
is still controversial, despite encouraging results in some clinical trials.
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Introduction
Despite improved medical care and support, and bet-
ter technological aspects of renal replacement therapy
(RRT), the mortality rate for patients with acute renal fail-
ure (ARF) has remained high and stable over more than
two decades, often exceeding 50%1-3. In particular, ARF is
more frequently seen as part of a more complex syndrome
defined as multiple organ failure (MOF). In this clinical
setting, patients are almost inevitably confined to intensive
care units (ICU), and sepsis is a frequent underlying mecha-
nism of organ failure4. Thus, the main causes of death are
the underlying disease and infection, not ARF itself5. The
mortality of RRT also may affect the outcome. For many
years, intermittent hemodialysis (IHD) has been a standard
form of dialysis to treat ARF. However, as a majority of
patients with ARF are hemodynamically unstable and have
severe concomitant diseases (sepsis, shock, MOF, acute
respiratory distress syndrome (ARDS)), many develop hy-
potension during IHD. Because of cardiovascular instabil-
ity, it is often not possible to accomplish the desired vol-
ume removal which, in turn, renders parenteral nutrition
and the administration of vasopressors more difficult6.The
evolution in the field of dialysis has led to a parallel devel-
opment in the therapeutic approach to patients suffering
from the syndrome of ARF. This progress has made pos-
sible to perform continuous renal replacement therapy
(CRRT) without major problems or complications char-
acteristic of IHD.
The aim of this paper is to descriebe and summarize the
most effective and promising options for treating ARF in
critically ill patients.
P. Kes Continuous renal replacement therapy
100 Acta clin Croat, Vol. 39, No. 2, 2000
History
Inability of ARF patients to tolerate the hemodynamic
effects of IHD was the very reason that motivated Kramer
et al.7 to initiate a new approach of continuous CRRT. In
March 1977, Kramer7 installed hemofiltration in a patient
and by mistake punctured femoral artery instead of the vein.
His presence of mind was the starting point of the continu-
ous arteriovenous hemofiltration (CAVH). The driving
pressure in the extracorporeal arteriovenous circuit was suf-
ficient for an effective continuous hemofiltration, and
ultrafiltrate was eliminated through the filter synchronously
with the pulsations in the systemic circulation8.
The initial technique was simple. The high-flux
hemofilter (Amicon Diafilter 20) was perfused (75 to 150
mL/min) via an extracorporeal arteriovenous circuit be-
tween the femoral vessels introduced by Seldinger tech-
nique. The ultrafiltration rate (UFR) was 200 to 600 mL/
h, and continuous anticoagulation was performed by add-
ing a 1,000 to 1,500 IU/h dose of heparin.
In the following years, the technique found wide use in
ICU. The special benefits of the method included its tech-
nical simplicity and lack of any pumping device, a remark-
able stability of the systemic circulation, an effective elimi-
nation of fluid, and an easy way for managing overhydration.
In the initial period, some severe and even fatal com-
plications resulted from the arterial access of the extracor-
poreal circuit, which included unintentional and unnoticed
disconnection of the blood line, bleeding and infection of
hematoma, arterial thromboembolization in arteriosclerotic
vessels, and other events. The limited removal capacity of
CAVH and the complications related to the arterial access
were the main reasons to look for a venovenous pump-
driven technique in order to become independent from the
systemic circulation and arterial access. As early as 1982,
Bischoff et al.9 used a continuous venovenous hemofiltra-
tion (CVVH) pump-driven technique. With a single roller
pump, it was possible to increase the UFR to up to 1,000
mL/h, and the removal of urea nitrogen was effective even
in severely catabolic septic patients. When higher flow rates
were necessary, the substitution fluid was kept warm by a
heating device. Another way to improve the solute clear-
ance was to combine the convective principle of hemofil-
tration with the benefits of the diffusive transport of dialy-
sis, which is more effective for the removal of small mol-
ecules. Geronimus and Schneider10 using a cuprophane dia-
lyzer, and independently Ronco11 using a polysulfone fil-
ter, developed a modification called continuous arterio-
venous hemodialysis (CAVH) or hemodiafiltration
(CAVHDF). In these systems, a dialyzer was connected to
the patient using a circuit similar to CAVH. In addition,
dialysate was circulated through the dialyzer. Adequate urea
clearance was achieved by diffusion with a remarkable car-
diovascular stability. It was evident that the addition of the
diffusive principle considerably improved the removal ca-
pacity of the hemoflitration8.Today, this combination with
the dialysis principle is integrated in all automatic pump
systems for CRRT.
Definitions and Nomenclature
Recently, a series of publications dealing with a tempta-
tive standardization of definitions, nomenclature and ab-
breviations in the specialized area of CRRT have appeared
on the international scene12. The recommendations based
on currently published articles and discussions incorporate
two basic premises: 1) definitions are to be based on the
operating characteristics of each method with emphasis on
the primary forces for solutes and fluid removal; and 2)
description of the components are not considered in the
definitions but should be mentioned in the method section
of any publication.
CRRT
CRRT is any extracorporeal blood purification therapy
intended to substitute for impaired renal function over an
extended period of time, and applied for or aimed at being
applied for 24 h/day. The various CRRTs differ in the type
of access (arteriovenous or venovenous), application of con-
vective clearance (continuous hemofiltration), diffusive
clearance (continuous hemodialysis), or a combination of
both (continuous hemodiafiltration), and location where
the replacement fluid enters the circuit (predilution or
postdilution) (Table 1).
CAVH
CAVH is a technique of CRRT whereby blood is driven
by the patient’s blood pressure through a filter containing
a highly permeable membrane via an extracorporeal circuit
originating from an artery and terminating in a vein. The
ultrafiltrate produced during membrane transit is replaced
in part or completely with appropriate replacement solu-
tions to achieve blood purification and volume control (Fig.
1, left panel). Ultrafiltration (UF) is in excess of patient
weight loss12.
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CVVH
CVVH is a technique of CRRT whereby blood is
driven through a highly permeable membrane by a peristal-
tic pump via an extracorporeal circuit originating from a
vein and terminating in a vein. The ultrafiltrate produced
during membrane transit is replaced in part or completely
with appropriate replacement solutions to achieve blood
purification and volume control. UF in excess of replace-
ment results in patient weight lossl2 (Fig. 1, right panel).
Slow Continuous Ultrafiltration
Slow continuous ultrafiltration (SCUF) is a form of
CAVH or CVVH not associated with fluid replacement
and often used in the management of refractory edema with
or without renal failure. Its primary aim is to achieve safe
and effective management of fluid overload (Fig. 2). In
venovenous SCUF, a volumetric control of UF may be re-
quired to maintain UFR below the values that would re-
quire fluid reinfusion12.
Table 1. Comparison of different continuous renal replacement modalities
Type of therapy Abbreviation Physicochemical basis Urea clearance (L/d) Convective (mL/min)
of therapy Diffusive Convective Diffusive Convective
Continuous arteriovenous CAVH Convection - 10-15 - 7-10
hemofiltration
Continuous venovenous CVVH Convection - 22-28 - 15-20
hemofiltration
Continuous arteriovenous CAVHD Diffusion plus small 22-24 2-6 14-16 2-5
hemodialysis amount of convection
Continuous venovenous CVVHD Diffusion plus small 22-24 2-6 14-16 2-5
hemodialysis amount of convection
Continuous arteriovenous CAVHDF Diffusion plus 22-24 14.4 18-20 10
hemodiafiltration convection
Continuous venovenous CVVHDF Diffusion plus 22-24 14.4 18-20 10-13
hemodiafiltration convection
Slow continuous SCVF Convection - 3.0 - 2-5
ultrafiltration
Mechanisms of function
Fig. 1. Schematic presentation of CAVH and CVVH therapy.
Abbreviations: A=artery, V=vein, Uf=ultrafiltrate, R=replacement fluid, P=peristaltic pump, Qb=blood flow, Qf=ultrafiltration rate,
TMP=transmembrane pressure, in=dialyzer inlet, out=dialyzer outlet.
CRRT techniques: CAVH · CVVH
CVVHCAVH
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CAVHDF
CAVHDF is a technique of CRRT whereby the
CAVH circuit is modified by the addition of slow counter-
current dialysate flow into the ultrafiltrate-dialysate com-
partment of the hemofilter. UF volumes are optimized to
exceed the desired weight loss to take advantage from con-
vection. Fluid replacement is routinely administered as
clinically indicated to replace fluid losses either in part or
completely. Solute removal is both diffusive and convec-
tive12 (Fig. 3, left panel).
CVVHDF
CVVHDF is a technique of CRRT whereby the
CVVH circuit is modified by the addition of slow coun-
tercurrent dialysate flow to the ultrafiltrate-dialysate com-
partment of the membrane. UFR is greater-than-expected
patient weight loss.Therefore, fluid replacement is routinely
administered as clinically indicated to maintain desired fluid
balance. Solute removal is both diffusive and convective12




Fig. 2. Schematic presentation of SCUF therapy.
Abbreviations: A=artery, V=vein, Uf=ultrafiltrate, R=replacement fluid, P=peristaltic pump, Qb=blood flow, Qf=ultrafiltration rate,
TMP=transmembrane pressure, in=dialyzer inlet, out=dialyzer outlet, UFC=ultrafiltration control system.
Mechanisms of function
CRRT techniques: CAVHDF - CVVHDF
CVVHDFCAVHDF
Fig. 3. Schematic presentation of CAVHDF and CVVHDF therapy.
Abbreviations: A=artery, V=vein, Uf=ultrafiltrate, R=replacement fluid, P=peristaltic pump, Qb=blood flow, Qf=ultrafiltration rate,
TMP=transmembrane pressure, in=dialyzer inlet, out=dialyzer outlet, Dial=dialysate, Qd=dialysate flow rate.
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CAVHD
CAVHD is a technique of CRRT whereby the extra-
corporeal circuit is characterized by slow countercurrent
dialysate flow into the ultrafiltrate-dialysate compartment
of the dialyzer. Blood flow through the blood compartment
of the dialyzer is driven by the patient’s blood pressure
through a circuit beginning in an artery and terminating in
a vein. Fluid replacement is not routinely administered.
Solute clearance is mostly diffusive12 (Fig. 4, left panel).
CVVHD
CVVHD is a technique of CRRT whereby the extra-
corporeal circuit is characterized by slow countercurrent
dialysate flow into the ultrafiltrate-dialysate compartment
of the dialyzer. Blood flow through the blood compartment
of the dialyzer is driven by a peristaltic pump through a
circuit beginning and terminating in a vein. Fluid replace-
ment is not routinely administered. Solute clearance is
mostly diffusive12 (Fig. 4, right panel). It should be empha-
sized that the mechanism by which solutes are removed
from the circulation in continuous hemodialysis may be
substantially different depending on the choice of the mem-
brane. If a low-flux cellulosic membrane is used, solutes are
mainly removed by diffusion, and ultrafiltration volume
equals patient weight loss. In case of a synthetic high-flux
membrane, solutes are removed both by diffusion and con-
vection. The UF would exceed the patient weight loss but
is limited by an UF-dialysate outlet control system that
avoids the need for postdilutional reinfusion. In this case,
the pressure profile inside the dialyzer leads to a proximal
filtration and distal backfiltration by which convective
transport is maintained even though it is absolutely not
apparent. This treatment has been defined as continuous
high-flux dialysis (CHFD).
CVVH/DF - extracorporeal membrane oxygenation or
CVVH/DF - Venovenous Bypass CVVH/DF - extra-
corporeal membrane oxygenation (ECMO) and CVVH/
DF - venovenous bypass are techniques of CRRT where
the driving force to blood flow across the filter is obtained
from a circuit derivation of the larger blood pump circuit
used from ECMO or venovenous bypass (as may occur
during liver transplantation)12.
Indications
CRRT is often regarded as one of the more important
advances in ICU in recent years. ARF combined with car-
diovascular instability, severe fluid overload, hypercatabo-
lism or cerebral edema are widely accepted indications for
CRRT. Less well established indications include sepsis
and other inflammatory syndromes, crush injury, ARDS,
tumor lysis syndrome, chronic heart failure, lactic acido-
sis, cardiopulmonary bypass, and ARF combined with
acute or chronic liver failure and after hepatic transplan-
tation. Recently, CRRT has been used in critically ill pe-
diatric patients6.
Mechanisms of function
CRRT techniques: CAVHD - CVVHD
CVVHDCAVHD
Fig. 4. Schematic presentation of CAVHD and CVVHD therapy.
Abbreviations: A=artery, V=vein, Uf=ultrafiltrate, R=replacement fluid, P=peristaltic pump, Qb=blood flow, Qf=ultrafiltration rate,
TMP=transmembrane pressure, in=dialyzer inlet, out=dialyzer outlet, Dial=dialysate, Qd=dialysate flow rate.
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ARF with cardiovascular failure
The most frequently failing organ in critically ill pa-
tients is the circulatory system. During RRT, the circulat-
ing volume is reduced by UF that is followed by re-
plenshment from the interstitial compartment. CRRT al-
lows slow and isotonic fluid removal that results in an ex-
cellent hemodynamic tolerance, even in patients with se-
vere fluid overload or septic shock. Fluid removal and sol-
ute clearance in CRRT may be modified at any time allow-
ing adaptation to the rapidly changing hemodynamic situ-
ation of critically ill patients. Improved hemodynamic sta-
bility during CRRT may have a beneficial effect on the
preservation and recovery of renal function13.
ARF with hypercatabolism
There is general agreement that hypercatabolic patients
require substantial caloric and nitrogen supply in order to
preserve lean body mass. This results in a high obligatory
fluid input. CRRT permits a safe and adequate control of
hydration, allowing the delivery of full dose nutrition13.The
hypercatabolic state of ARF patients requires efficient re-
moval of nitrogen waste products. Inadequate azotemia
control has for a long time been regarded as one of the
drawbacks of CRRT. However, this shortcoming only ap-
plies to CAVH. The addition of dialysis and the use of
pump driven techniques allow urea clearances of 20 to 50
mL/min to be achieved12. For the same adequacy of
azotemia control (Kt/V) CRRT achieves a better metabolic
control than IHD14.This superior metabolic control results
from continuous equilibration between the different body
compartments, allowing access to the total distribution
volume of the solute, thus increasing the amount of solute
removed. During IHD, solute concentration decreases re-
sulting in a decrease in the amount of solute removed (even
if clearance is constant). This intermittent treatment is fol-
lowed by a rebound of the solute concentration due to re-
distribution from the peripheral compartment to the cen-
tral compartment. In critically ill patients, post-treatment
rebound of solute concentrations is aggravated by distur-
bances of the regional circulation that may further decrease
tha actual volume of distribution to which the intermittent
treatment has access15.
ARF with cerebral edema
Life-threatening elevations of the intracranial pressure
may occur during IHD in patients with pre-existing cere-
bral edema secondary to ischemia, metabolic disorders
(such as liver failure), trauma or surgery. CRRT induces a
slow and gradual decrease of plasma osmolality and thus
prevents dialysis disequilibrium. The improved hemody-
namic stability further contributes to the preservation of
cerebral perfusion pressure. Patients with renal failure com-
bined with cerebral edema should therefore be treated with
CRRT.
Sepsis and other inflammatory syndromes
Extracorporeal removal of several inflammatory media-
tors including proinflammatory cytokines, activation prod-
ucts or components of the complement system, and arachi-
donic acid metabolites has been demonstrated in a great
number of uncontrolled clinical studies. However, a de-
crease in the plasma concentration during CRRT is more
an exception than the rule, possibly due to the ongoing
production and the high endogenous clearance limiting the
contribution of extracorporeal elimination. Two recent con-
trolled clinical studies did not establish an effect of
hemofiltration on the plasma concentrations of  TNF-(and
interleukin-6 (Il-6)16,17. The use of high volume hemo-
filtration might increase the contribution of extracorporeal
clearance, whereas frequent filter changes might increase
the elimination of mediators adsorbing to the membrane.
Many uncontrolled clinical studies report on a remark-
able hemodynamic and respiratory stability, and occasion-
ally improvement of septic patients on hemofiltration. Only
a limited number of small controlled clinical trials evalu-
ated the effect of zero-balanced hemoflitration in hyper-
dynamic inflammatory syndromes and demostrated no ef-
fect or attenuation of the hyperdynamic situation. A reduc-
tion of body temperature or correction of metabolic disor-
ders might have contributed. Clinical application of high
volume hemofiltration has only been reported in uncon-
trolled trials, suggesting an improvement of hemodynam-
ics in patients with septic shock or inflammation after car-
diopulmonary bypass15. An improvement of the survival or
a reduction of organ failure during CRRT in patients with
inflammatory syndromes remains to be confirmed in con-
trolled clinical studies. The underlying mechanism of this
amelioration also requires further investigations. Awaiting
the results of this research, widespread application od
CRRT in patients that have not yet developed ARF can-
not be recommended.
Crush syndrome
Hemofiltration has been suggested to contribute to the
prevention of ARF in crush injury by extracorporeal elimi-
nation of myoglobin (MW 17. 8 kD)18. However, adequate
fluid resuscitation combined with urinary alkalization re-
main the mainstays in the treatment of crush syndrome.
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Acute respiratory distress syndrome
Elimination of inflammatory mediators and an excess
of extravascular lung water have been suggested to improve
the outcome of ARDS19,20. CRRT-induced hypothermia
may be used in patients with ARDS in order to reduce C02
production. The decreased ventilatory requirement may
reduce ventilator-induced lung injury.
Tumor lysis syndrome
Tumor lysis syndrome may lead to ARF due to tubular
obstruction by hyperphosphatemia with precipitation of
calcium and phosphate complexes or uric acid crystals in
renal tubuli and interstitium21. The prevention of ARF in
tumor lysis syndrome relies on the stimulation of diuresis
combined with allopurinol, and high-risk patients who have
low urine output and high plasma LDL-cholesterol con-
centration may be treated with CRRT22.
Congestive Heart Failure
In congestive heart failure, low cardiac output promotes
a variety of compensatory neurohumoral mechanisms (ac-
tivation of the sympathetic system, and the renin-angio-
tensin-aldosterone system, and release of vasopressin), re-
sulting in both sodium accumulation and water retention,
as well as in arteriolar vasoconstriction (Fig. 5). The treat-
ment of congestive heart failure requires an interruption in
the vicious neurohumoral hemodynamic circle, and this
may be mostly achieved with diuretics, vasodilatators, and
beta-blocking agents. Some patients with congestive heart
failure will not respond to medical treatment, and even
more fluid removal with diuretics may further enhance the
neurohumoral stimulation and aggravate heart failure. The
removal of fluid with UF has been reported to interrupt this
vicious circle and represents an alternative approach in the
treatment of refractory heart failure23.The data suggest that
fluid removal by UF shifts the abnormal set point for fluid
balance to a more physiological level, resulting in an increase
of diuresis and sodium excretion, stabilizing blood pressure,
and a further decrease of body weight after interruption of
the procedure. Continuous therapies are particularly suited
for patients with severe heart failure, to bridge the time until
heart transplantation can be performed24.
Lactic acidosis
Continuous bicarbonate hemodiafiltration may elimi-
nate lactate, and minimize hypernatremia and hyperv-
olemia (both of which are side effects of bicarbonate ad-
ministration) contributing to the correction of lactic acido-
sis25.
Cardiopulmonary bypass
The primary goal of continuous UF during cardiopul-
monary bypass is to remove excess fluid from overhydrated
patients, to reduce blood loss and transfusion requirement,
to improve pulmonary vascular resistance and oxygenation,
to improve left ventricular systolic and diastolic function,
and to remove inflammatory mediators by convective sol-
ute transport26.
ARF with acute or chronic liver failure
CRRT is now established as the treatment of choice for
the management of ARF in the setting of either acute or
chronic liver failure, and after hepatic transplantation. The
treatment alone does not provide adequate compensation,
as the amount of hepatic toxins such as ammonia removed
during CRRT is small. However, CRRT does have a role
in the management of both acute and chronic liver failure
awaiting transplantation by allowing the correction of so-
dium and other electrolyte imbalances, providing space for
parenteral nutrition and albumin, and controlled extracel-
lular fluid removal. A biocompatible membrane such as
polysulphone or polyacrylonitrile should be used to mini-
mize both adverse cardiovascular and intracranial effects.
The anticoagulant of choice is prostacyclin because it not
only reduces the risk of hemorrhage, but may also increase
tissue oxygenation.
Critically ill pediatric patients
CRRT either driven in the arteriovenous or venovenous
mode is an effective method of renal support in critically
ill infants and children. Both methods allow good control
of fluid, acid-base, and electrolyte balances. The pump-
Fig. 5. Schematic presentation of the vicious circle relating cardiac
failure and functional ARF, and the role of isolated UF.
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driven CRRT mode allows constant blood flow and UFR
with excellent control of azotemia even in hypercatabolic
states (urea clearance may increase up to 300%). The use
of a pump makes the CRRT more complex, but it can be
performed in every pediatric ICU. CVVH, CVVHDF or
CVVHD, because of the highest urea clearance rates are
indicated in emergency conditions such as severe tumor
lysis syndrome or severe metabolic crisis due to an inborn
error of metabolism. All CRRTs allow adequate nutrition
and unlimited medication of critically ill pediatric pa-
tients26.
Prophylactic use of CRRT
The prophylactic initiation of CRRT is not justified in
a patient with completely normal renal function, with an
unimpaired water excretion and normal hemodynamic
function. Potential advantages cannot outweigh the risks
associated with this invasive therapeutic approach, and
there is no evidence that prophylactic CRRT will prevent
the development of renal failure in such a patient. How-
ever, prophylactic CRRT in modern critical care medicine
may be viewed in the more complex context of a multiorgan
approach with effects on various additional, but not only
renal, organ functions. This may become especially impor-
tant in sepsis, septic shock and MOF, the most frequent
causes of ARF in the critically ill. Any therapeutic approach
in these conditions in preventing the development of mul-
tiple organ dysfunctions such as heart failure, ARDS, in-
testinal failure aside from renal failure must take into ac-
count the basic pathophysiologic pancellular disturbance.
In the critically ill patient with compromised water excre-
tion, cardiovascular instability, and sepsis at risk of progres-
sion to MOF, and patients with ARDS and progressive
water accumulation, the early institution of CRRT is war-
ranted even when laboratory values would only suggest a
mild impairment of renal function27.
New Technology and New Techniques for CRRT
The CRRT Equipment
Minimal technical requirements for CRRT are a blood
pump, a dialyzer or hemofilter, arterial and venous pressure
monitors, a venous air bubble chamber, an air detector, and
a balancing system for dialysate inflow and outflow, replace-
ment fluid inflow, and filtrate outflow (Fig. 6).
The Prisma (Hospal, France) consists of 4 pumps for
blood, dialysate, replacement fluid and effluent, and 3
weighing devices. The touch screen along with software
provides step-by-step instruction and online assistance. A
disposable tubing set with a preconnected AN69 filter al-
lows an easy set-up.
The BM 25 (Baxter Healthcare, USA) consists of 2
integrated modules, i.e. a blood monitor BM 11, and a
balancing monitor BM 14 with 2 pumps for the inflow of
dialysate and replacement fluid, and outflow of dialysate
and filtrate, as well as 2 integrated scales.
The Trio (Braun, Germany) is composed of a blood
module and 2 fluid balance monitors operated by interfaced
roller pumps. The front panel resembles the infusion
pumps. A disposable measuring chamber with an ultra-
sound sensor controls fluid balance, and the pumps are
recalibrated after each measurement cycle.
The Diapact (Braun, Germany) performs CVVHDF.
The blood is pumped into a high-flux dialyzer in which
proximal part UF-induced convective clearance occurs. In
addition, diffusive clearance is applied by a dialysate flow
between 20 and 100 mL/min countercurrent to the blood
flow. As blood courses down the hollow fiber and plasma
water is filtered, the pressure in the dialysate compartment
exceeds in the distal part the pressure in the blood compart-
ment.This causes backfiltration of sterile dialysate into the
blood and compensates for the UF in the proximal part.
Equilibration between the dialysate and plasma is achieved
by optimal recirculation of the dialysate and 10 L of dialy-
sate can be recirculated in approximately 4 hours. The
machine produces high small-molecule clearance (the com-
bined diffusive and convective clearance for urea is about
60 L/day), and a high middle-molecule clearance.
Fig. 6. Schematic diagram of the system for continuous high-flux di-
alysis.
The module used for either slow continuous UF (SCUF) or slow daily
UF (SDUF) consists of two independent pumps (one for blood, and
one for UF) plus venous pressure monitoring module and air detector
with safety clamp.
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The EQUAsmart (Medica, Italy) is equipped with 2
peristaltic pumps for blood and replacement fluid, 2 intel-
ligent clumps (one for control of dialysate and the other for
effluent flow during SCUF), and 3 accurate load cells (for
UF, replacement solution, and dialysate). A thermal printer
is integrated in the EQUAsmart body to enclose treatment
data in patient clinical report. EQUAsmart has been spe-
cifically developed to improve the working condition for the
filter, to ensure its proper function along with the treatment
duration, and to avoid undesired and premature replace-
ment. For these reasons, the blood flows from the bottom
to the top avoiding the build up of air bubbles on the
hemofilter top. In addition to this, when dialysate flow is
needed also the dialysate flows from the bottom to the top
in a concurrent way, giving, at low dialysate flow, similar
results to the traditional countercurrent flow. The UF of the
hemofilter is not forced by the use of a pump but is free de-
pending on the characteristics of both the filter and patient,
and ensuring a spontaneous, unforced UF, less stress for the
patient, users work load reduction, and saving of economic
resources.
The Acu-men (Fresenius Medical Care, Germany) uses
a pneumatic blood pump to drive the blood through the
extracorporeal circuit, and the venous air bubble chamber
is replaced by 2 hydrophobic membranes. Negative pres-
sure behind these membranes continuously removes the air
entering the system. Accurate balancing is achieved by a
volumetric balancing chamber. The extracorporeal circuit
is integrated in a disposable cartridge, which ensures an easy
set-up.
Slow continuous dialysis (SCD) is defined by the follow-
ing parameters: 1) blood flow from 100 to 500 mL/min; 2)
dialysate flow from 100 to 300 mL/min; 3) utilization of a
modified 2008H hemodialysis machine (Fresenius Medi-
cal Care, Germany) with controlled UF and online produc-
tion of bicarbonate-based dialysate; and 4) continuous or
daily treatment for at least 8 to 12 hours. SCD provides a
sustained high rate of solute clearance in the range of 70
to 80 mL/min. Preliminary clinical data demonstrate the
safety, simplicity, and efficiency of the treatment.
The purpose of the technique of coupled sequential
hemofiltration and hemodialysis is to accomplish sequential
Fig. 7. Cytokine removal from ultrafiltrate by charcoal cartridge used in coupled filtration-adsorption system.
Cytokine concentration in the inlet ultrafiltrate is increasing during the first 15 min of treatment, because at the beginning adsorption onto
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fluid removal and then solute removal in patients who are
unable to tolerate simultaneous UF and diffusive solute
clearance as it occurs during routine IHD. With the advent
of computed volumetric controlled UF machines and so-
dium modeling, the incidents and severity of hypotension
are decreasing, and the above methods are used much less
frequently.
In the coupled filtration-absorption technique used in the
treatment of sepsis, a plasma filter is used in a continuous
hemofiltration circuit. The plasma filtrate passes through
an uncoated charcoal cartridge and is reinfused to the pa-
tient.The system offers the ability to remove inflammatory
mediators in sepsis28 (Fig. 7), protein-bound or lipid-
soluble toxins in combined renal and liver failure29.
Temporary vascular access for CRRT
Initially performed spontaneously via an arteriovenous
circuit, CRRT modalities have progressively become
venovenous with the circulatory assistance of a blood pump.
At present, double lumen catheters represent the most com-
mon vascular access for CRRT. Semirigid polyurethane
catheters currently used in case of emergency are limited
in short term use, and flexible silicone catheters, less aggres-
sive for the vessels, seem better suited for the medium and
long-term run. The internal jugular vein, particularly the
right one, seems to warrant proper functioning of the cath-
eter while reducing the risk of stenotic complications. Sub-
clavian access should be limited in time and reserved for
silicone catheters in order to limit the risk of stenosis and/
or thrombosis. Femoral access, very useful in case of respi-
ratory problems and in case of emergency, should also be
limited in time to prevent thrombosis and/or infection.
Performance standards of catheters are less of a limiting
factor in CRRT modalities than in IHD ones30. Finally,
careful handling of the catheter is essential to prevent in-
fections31.
Anticoagulation
Patency of the extracorporeal circuit requires the use of
continuous anticoagulation, which adds to the risk of com-
plications (bleeding) and requires monitoring. Several
methods of anticoagulation are now in use, and it is pos-
sible to minimize the risks (Table 2).
The most commonly used method of prevention clot-
ting is continuous administration of heparin in the arterial line
of the extracorporeal circuit. The hemofilter is primed with
one to 2 L of heparinized saline containing 2,500 to 5,000
U heparin. This is followed by an initial loading heparin
dose of 1,000 to 2,000 U. Routine coagulation parameters
guide the subsequent continuous heparin administration of
roughly 400 to 800 U/h (5 to 10 U/kg body weight)32. A
partial thromboplasin time or activated clotting time
(ACT) of 1.5 to 2 times the normal is the usual target level
of anticoagulation. The incidence of heparin-induced ma-
jor bleeding complications may be as high as 50%, and ap-
proximately 4% of such patients die as a result of hemor-
rhages during CRRT.
Priming the extracorporeal circuit with 2 L saline with
20,000 U heparin for one to 4 h before initiation of treatment
leads to significant heparin adsorption onto the hemofilter
surface, which seems to reduce the need for heparin dur-
ing CRRT.
Regional heparin anticoagulation with protamine neutral-
ization at a ratio of 100:1 aims to minimize the systemic
effect of heparin. The method requires frequent monitor-
ing to optimize the heparin to protamine ratio.
Table 2. Anticoagulation for continuous renal replacement therapy
Anticoagulation Advantages Problems Efficacy Monitoring
Heparin Good anticoagulation Bleeding, thrombocytopenia Good PTT/ACT
Low molecular weight heparin Less thrombocytopenia Bleeding Good Anti-Xa activity
Regional Reduced bleeding Complex Good PTT/ACT
heparinization + protamine
neutralization
Citrate Lowest risk of bleeding Metabolic disorders, Excellent PTT/ACT
   special, dialysate
Prostacyclin + (low-dose
heparin) Reduced bleeding risk Severe hypotension Insufficient Thrombelastograph
Saline flush No bleeding risk Filter clotting Insufficient
Abbreviations: PTT = partial tromboplastin time, ACT = activated clotting time.
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Low molecular weight heparin in a dose to achieve a con-
centration of 0.3 to 0.6 antiXa U/mL is less likely to cause
thrombocytopenia compared with ultrafractionated hep-
arin.
Regional citrate anticoagulation is associated with the
lowest risk of bleeding and dialyzer clotting, but it is only
suitable for methods that use diffusive clearance (convec-
tive clearance during CRRT removes insufficient amounts
of citrate), and a special alkali- and calcium-free dialysate
with low sodium concentration (calcium supplementation
is necessary during CRRT).
Prostacyclin is a potent inhibitor of platelet aggregation,
and in comparison with heparin it appears to reduce bleed-
ing frequency and to increase hemofilter life. It is also a
potent vasodilatator and may induce a marked decrease in
the mean arterial pressure (up to 15 mm Hg). Furthermore,
the drug is expensive and monitoring of platelet function
is difficult6.
Dialysis membranes used in CRRT
It has been increasingly recognized that significant side
effects may occur as a result of interactions of blood with
the dialysis membrane itself32,33. The use of unmodified
cellulosic HD membranes results in a potent activation of
the alternative pathway of complement, granulocyte acti-
vation and degranulation, protease release, production of
reactive oxygen species, and modulation of granulocyte cell
adhesion molecules, contributing to the prolongation of
ARF, and increasing the morbidity and mortality32-34. Most
of the studies32-35 suggest that dialysis (IHD or CRRT)
with more biocompatible membranes (modified cellulosic
or synthetic) in patients with ARF leads to better outcome.
In a complex disease such as sepsis or ARDS, down-
regulation of the ongoing systemic inflammatory response
may be beneficial. The use of highly adsorptive membranes
in CRRT procedure results in simultaneous inhibition of
different biological systems (e.g., complement, coagulation,
cytokines, kinins)36, and frequent changes of dialyzers or
development of new devices with greater adsorptive capac-
ity may represent therapeutic advances for critically ill pa-
tients with MODS.
The technical aspects of CRT have set the minimal re-
quirements for hemofilters and hemodialyzers. CVVH uses
a TMP of 100 to 150 mm Hg. A desired UF of 25 mL/min
(1. 5 L/h) requires a TMP of 120 mm Hg and a membrane
with an UF coefficient of 12. 5 mL/h/mm Hg. In SCD,
the blood flow rate (100 to 150 mL/min) is many times
greater than the dialysate flow rate (14 to 30 mL/min),
which results in almost complete saturation of the dialysate.
The minimal requirement for dialysis membranes is a mass
transfer coeffcient (KoA) high enough to provide a urea
clearance of up to 30 mL/min. All current membranes by
far exceed this KoA, and most of the filters also can be used
for combined filtration and dialysis (CVVHDF)6.
Replacemet fluid and dialysate
Any fluids with the following concentrations of electro-
lytes are adequate as substitution fluid for CVVH: sodium
140 mmol/L, potassium 0 to 4 mmol/L, calcium 1.5 to 1.75
mmol/L, magnesium 0.5 to 0.75 mmol/L, chloride 108 to
112 mmol/L, and glucose 0 to 83.3 mmol/L. Most of the
available replacement solutions contain lactate (3 5 to 45
mmol/L) to compensate for bicarbonate losses in the fil-
trate (up to 1,000 mmol/day during CVVH or CVVHD).
Under physiologic conditions, lactate is converted to bicar-
bonate on an equimolar basis at a rate of roughly 100 mmol/
h. Severe impairment of lactate metabolism or enhanced
lactate production in patients with sepsis, liver failure, or
severe hypoxia may result in lactate accumulation with de-
creased myocardial performance. The negative metabolic
and hemodynamic effects of lactate make the buffer bicar-
bonate preferable37 (Fig. 8). In a twocomponent system, a
bicarbonate solution (160 mL 8.4% HCO3) is mixed im-
mediately before use with 4,500 mL electrolyte solution
containing calcium, magnesium, and lactic acid (3 mmol/
L). Lactic acid increases pCO2 and prevents precipitation
of insolubile calcium and magnesium carbonates. The so-
lution is stable for 24 hours.
For SCD, replacement solutions for hemofiltration or
peritoneal dialysis fluid with the abovementioned electro-
lyte concentrations are frequently used as dialysate6. Some
peritoneal fluids contain less than 140 mmol/L sodium, and
hypertonic saline must be added to increase the sodium
concentrations and to avoid hyponatremia.
UF control during CRRT is achieved by means of grav-
ity, by using an ultrafiltration pump, or by two identically
calibrated pumps (one for UF/dialysate inflow and one for
the replacement fluid and dialysate outflow). Newer devices
with gravimetric or volumetric balancing systems provide
a more accurate fluid balance.
The continuous blood flow through extracorporeal sys-
tem and cool replacement fluid cause a reduction in body
temperature, and an energy loss (about 1,000 kcal/day). The
reduction of body temperature may be desirable in certain
critically ill patients, in whom hypothermia is associated
with a reduction of oxygen consumption, an increase in
pO2, and increase in systemic vascular resistance and blood
pressure. In most patients, it is recommended to use a heat-
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ing device to warm the substitution fluid and to prevent
hypothermia during CRRT.
Metabolic control and dialysis dose in CRRTs
Urea clearance in CRRT is equivalent to the UF. Dur-
ing CAVH and CVVH, roughly 10 to 15 L and 22 to 24 L
of plasma water are filtered per day, which corresponds to a
urea clearance of 10 to 15 L/day and 22 to 24 L/day, respec-
tively. Because the blood flow during CRRT is much greater
than the dialysate flow, the dialysate is fully saturated with
urea. The urea clearance in CAVHD or CVVHD equals the
dialysate flow rate plus UF. Roughly 24 to 30 L of plasma
water are cleared per day during continuous HD. Continu-
ous HDF, a combination of convective and diffusive clear-
ance, is the most efficient CRRT modality, providing a urea
clearance of 36 to 38 L/day. If it is not sufficient, the dialy-
sate flow rate may be increased to 4 L/day, which amounts
to a urea clearance of 3 L/day6.
The standards for dialysis adequacy in ARF are not cur-
rently defined. Considering the fact that ARF is a catabolic
state due to concomitant sepsis, wasting, acidosis, and in-
creased nutritional support, it would appear that ARF pa-
tients may require large dialysis dose delivery for metabolic
and azotemic control. Recently, urea kinetic modeling
(UKM) has been applied to estimate dialysis dose delivery
in ARF patients38. Clark et al.38 studied the control of
azotemia in 11 oliguric ARF patients treated by CVVH, and
compared these results with those of 11 ARF patients treated
by IHD. These studies have shown that intensive IHD (with
a urea clearance of 160 mL/min, performed for 4 h) would
be required 5 days per week to reach the dialysis dose and to
achieve the metabolic control equivalent to those achieved
with CVVH38.
Solute removal during CRRT is determined by convec-
Fig. 8. Urea generation rate obtained from critically ill patients treated
with CAVH using either lactate- or bicarbonate-based fluids.
The use of bicarbonate-based fluids was associated with a lower urea
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Table 3. Mean results for weights, urea clearances, ultrafiltration rates, and daily and weekly Kt/V obtained with four
different continuous replacement modalities and intermittent hemodialysis
Technique Weight Urea Cl UF Daily Weekly
(kg)  (mL/min)  (L/h)  Kt/V  Kt/V
4-h HD daily 71.6 175 Variable 1.07 7.5
4-h HD 3x/wk 7.16 175 Variable 1.07 3.2
CAVHD; DFR at 1 L/h
Multiflow-60 (PAN 0.6 m2) 73.0±3.0 23.0±2.2 0.5±0.1 0.88±0.12 6.2
CAVHD; DFR at 4 L/h
Multiflow-60 67.6±17.9 49.0±1.3 0.6±0.1 2.03±0.51 14.2
CVVHD; DFR at 1 L/h
Multiflow-60 81.2±7.4 34.8±4.3 1.1±0.3 1.14±0.25 8.0
CVVHD; DFR at 1 L/h
Multiflow-100 (PAN 0.9 m2) 63.9±12.4 43.7±3.2 1.6±0.2 1.83±0.39 12.8
Kt/V obtained with 4 hr IHD sessins are theoretical, assuming dialyzer urea clearance of 175 mL/min and considering mean weight
of all patients.
Abbreviations: IHD = intermittent hemodialysis, DFR = dialysate flow rate, UF = ultrafiltration, CAVHD = continuous arterio-
venous hemodialysis, CVVHD = continuous venovenous hemodialysis
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tive fluxes relating to UF, with urea clearances approach-
ing 10 to 15 mL/min. Perfusing the dialysate compartment
with dialysate increases solute clearances by adding a dif-
fusive component to clearance. Bonnardeaux et a1.39
showed that urea clearance increased from 24.6±1.3 mL/
min with a dialysate flow rate of 1 L/h to 48.5±3.4 mL/min
when the dialysate flow rate was increased to 4 L/h.
Leblanc et al.40 compared dialysis dose delivery by
CRRT and IHD in 25 critically ill ARF patients. Dialyzer
urea clearance was calculated directly by dialysate quanti-
fication, and urea clearances were calculated taking into
account dialysate and ultrafiltrate outflow rate, as well as
outlet dialysate and ultrafiltrate urea concentration. Volume
distribution of urea was estimated at 55% of the mean body
weight for each patient during CRRT. The mean Kt/V
obtained with the various CRRT modalities was compared
with a theoretical Kt/V of  l.l provided by IHD (4 h/ses-
sion utilized 3 times per week, or daily ). The data presented
in Table 3 show that CRRT may provide a greater dialysis
dose to ICU ARF patients40. Even more, because of rela-
tively large pore membranes used in CRRT modalities, and
of very high UF, CRRT methods are very effective in the
removal of toxic middle molecules, which may be impor-
tant in the treatment of patients with MOF and ARF.
Drugs and dosage during CRRT
Most drugs have a MW up to 0.5 kD and easily pass
through typical high-flux membranes (pore size 0.2 to 30
kD) used for CRRT. Because of the pore size of the dialy-
sis membranes, only protein-bound drugs will not pass
through the membrane. In postdilution hemofiltration, the
drug clearance equals the ultrafiltration rate, while in predi-
lution hemofiltration, the dilution prior to filtration needs
to be considered when calculating clearance. In continuous
HD, drugs are eliminated by diffusion (Fig. 9). The clini-
cal relevance of a given drug clearance caused by CRRT will
mainly depend on the competing drug clearance by other
elimination pathways. Even a high clearance for a drug may
Fig. 9. Continuous renal replacement therapy results in different drug clearance rates depending on the treatment modality used.
A) In postdilution hemofiltration, ultrafiltrate is saturated to 100% compared with the drug concentration in plasma water. The drug clear-
ance equals the UFR.
B) In predilution hemofiltration, the drug concentration is diluted by substitution fluid prior to entry into the dialyzer, resulting in lower satu-
ration of ultrafiltrate compared with the patient’s plasma water. The clearance is lower than the UFR.
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be irrelevant for overall drug removal if nonrenal clearance
pathways provide a much higher clearance rate. The ideal
drug to be removed by CRRT that requires dose adjustment
has low protein binding, low volume of distribution, and
low nonrenal clearance (e.g., aminoglycosides, flucytosine,
fosfomycin, and vancomycin)41.
Depending on the drug, it may be more appropriate to
increase the dose or to shorten the dosing interval. In the
antibiotics in which the bactericidal effect correlates with
peak concentrations (e.g., aminoglycosides), after beginning
CRRT, it is preferable to increase the single daily drug dose
to achieve high peak levels, while at the same time CRRT
treatment helps decrease the drug levels to low trough con-
centrations and thereby reduces the risk of side effects. The
efficacy of other antibiotics (e.g., beta-lactams) may be re-
lated to plasma concentrations above the minimal inhibi-
tory concentrations of the bacteria, whereas side effects
occur if high peak concentrations are reached with the use
of high single doses. In these drugs it may be useful to
shorten the dosing intervals instead of increasing the indi-
vidual dose41. Whenever feasible, the measurement of drug
concentrations should be used to guide the therapy. The
dose adjustments in CRRT patients are mostly based on
clinical studies in ICU patients42.
Advantages of CRRT
CRRT avoids nonphysiological volume overload, and
large fluctuations of the urea, creatinine, electrolyte and
acid-base balance, which occur because of intermittent
nature of HD treatment.
Fluid balance
Patients with MOF or sepsis require large amounts of
volume in the form of blood products, vasopressors, and
parenteral nutrition. Continuous therapies provide an al-
most unlimited ability to remove fluid which, in most pa-
tients, achieves an optimal volume balance.
Unlimited alimentation
The unrestrained fluid removal permits adequate pa-
renteral nutrition without the fear of inducing volume over-
load. Bellomo et al.43 demonstrated that 90% of patients
received the prescribed nutrition during CRRT, as oposed
to only 54% of patients during IHD. A subsequent study
showed that 91% of the patients were able to receive more
than 1.5 g protein/kg/d during CRRT, oposite to IHD and
peritoneal dialysis treated ARF patients who received only
up to 1.0 and 0.8 g/kg/d, respectively. CRRTs have also a
direct impact on amino acids and calorie loss. Depending
on the UFR during CVVH the body loses approximately
5 to 8 g/d amino acids (0.25 to 0.4 g/L). The administra-
tion of amino acids should therefore be increased by 0.2 g/
kg/d to compensate for these losses. CVVH also filters 40
to 80 g/d glucose, which should be substituted by the re-
placement fluid or parenteral nutrition. If dextrose-contain-
ing peritoneal dialysis fluid is used as dialysate in CVVHD,
roughly 45% to 60% of the dextrose are adsorbed resulting
in daily uptake of 700 to 1,300 kcal6. McDonald et a1.44
and Barlett et a1.45 observed that CRRT patients received
12% more protein than prescribed, as well as an optimal
caloric intake, which was associated with a trend toward a
lower mortality rate, compared with IHD (72% vs 88%).
Gradual urea removal
Continuous therapies avoid the fluctuations in blood
urea and sodium concentrations with a decrease in blood
osmolality and creation of an intracellular to blood concen-
tration gradient, which may lead to an osmotic shift of in-
travascular water to the interstitial and intracellular space.
This disequilibrium may cause cerebral edema with nau-
sea, vomiting and headache. During CRRT, serum osmo-
lality does not change significantly.
Hemodynamic stability
Hypotension is one of the most common and severe
complications of IHD, occurring in 20% to 50% of all treat-
ments6.The repeated episodes of hypotension during IHD
might aggravate renal injury and delay recovery from renal
failure46. It has been shown that HD associated hypoten-
sion and the increased need of catecholamines result in inc-
reased oxygen consumption, decreased splanchnic blood
flow, and increased interstitial, intramucosal acidosis47. In
comparison to patients treated with IHD, ARF patients
treated with CRRT experianced a significantly lower de-
crease in creatinine clearance (-7% vs -25%) and urine out-
put (-10% vs -50%)48.  Improved hemodynamic stability
during CRRT seems to have a protective effect on residual
kidney function, and improve cardiovascular stability.
Lower intracranial pressure
CRRT modalities appears to be beneficial in patients
with combined fulminant hepatic failure and ARF, and in
patients with increased intracranial pressure49.
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Elimination of septic mediators
The role of CRRT as a method of reducing serum
cytokines in septic ARF patients is still controversial. Many
inflammatory mediators (complement and cytokines) have
a molecular weight (up to 50 kD) below the cutoff point
of hemofilters, and have been detected in the filtrate of
septic patients as well as at the surface of dialysis mem-
branes50,51, suggesting removal by convective clearance as
well as membrane adsorption. An effective removal is only
possible with a highly permeable membrane (sieving coef-
ficient approximetely 1.0), high filtrate volume (>2 L/h),
and when the halflife of the substance to be eliminated is
greater than 60 min. Adsorption of TNF-α, IL-1β, factor
D, and platelet activation factor onto PAN69 membrane
is relatively high6,36,50-52. However, because the membrane
surfaces are saturated after a few hours, frequent filter
changes are necessary for them to generate effective adsorp-
tion of these mediators. Despite filter changes, only a brief
and transient drop in the inflammatory mediators plasma
level has been observed50,51. This does not mean that
CRRT (especially CVVHDF) cannot positively influence
sepsis or systemic inflammatory response syndrome (SIRS)
in other ways. Controlled clinical trials are needed to de-
termine whether or not CRRT actually has a beneficial
effect on outcome in septic ARF patients.
Difficulties and Unsolved Problems with
CRRT Modalities
CRRTs are generally well tolerated with a low rate of
complications. The potential complications are illustrated
in Table 4.






Catheter and circuit Infection and sepsis
kinking
Insufficient blood flow Allergic reaction
Line-catheter Hypothermia
disconnection
Air embolism Nutrient losses
Fluid balance errors Insufficient blood purification
Loss of efficiency Hypotension, arrhythmias
The most severe technical complications are mainly
associated with the arterial access of the CAVH procedure.
The vascular access malfunction (insufficient blood flow and
circuit clotting) occurred frequently in CAVH when spon-
taneous arteriovenous gradient moved the blood through
the circuit. Except in case of technical defects, the safety
system excludes any air embolism. At the high perfusion rate
of the extracorporeal circuit, any accidental disconnection of
the blood lines acutely threatens life. It must always be as-
sured that all connections are well locked and that the whole
circuit is freely visible. If there is an alarm failure of blood
pump, dangerous variations in the pressures may occur in-
side the circuit, and occasionally the circuit may even explode.
A significant reduction in membrane permeability frequently
occurs in CAVH (because of filter clotting), and it may
occur even in CVVH over time53. The sieving coefficient
of solutes tends to decrease, and the effective solute removal
may be less than expected because of this phenomenon. Ac-
cidental fluid overload is a consistent danger of the CRRT,
especially when a high fluid turnover is maintained53. Mo-
nitoring of fluid intake and output is mandatory.
The need for anticoagulation is regarded as the major
clinical disadvantage of CRRT53,54. In addition, platelet-
membrane interaction, turbulent blood flow, and shear
stress may cause platelet dysfunction, which further in-
creases the risk of bleeding54.The incidence of heparin-in-
duced bleeding complications can be as high as 50%, and
approximately 4% of such patients die as a result of hem-
orrhages during CRRT33.
The degree to which filter coagulation occurs may be
reduced by an uninterrupted blood flow, by monitoring of
activated clotting time and prothrombin time, and by lim-
iting the rates of volume depletion to about one L/h.
During CRRT treatment a considerable loss of amino
acids occurs, while glucose is taken up from the substitu-
tion solution6.
Deficiencies with respect to potassium and phosphate may
frequently occur due to electrolyte filtration, but also due
to a shift from the extracellular to the intracellular space
when nutrition therapy is started and the acid-base balance
is corrected55.
CRRT may be accompanied by other unrecognized
deficiencies of vitamins, trace elements, and other micronutri-
ents as well as with loss of some drugs55.
Significant disadvantages cited for CRRT are also ar-
terial puncture (necessary in CAVH, CAVHDF and
CAVHD) and immobilization of the patient. Arterial punc-
ture can be avoided by pump-assisted venovenous meth-
ods, and critically ill patients are in any case generally im-
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mobilized because of the primary disease. Hypothermia
provided by the hemofilter/dialyzer (that can be considered
a potent heat exchanger) must be taken into consideration
when the caloric intake is scheduled and the nutritional and
energy balances are evaluated53.
Currently used CRRT with sophisticated treatment
devices has become more expensive than IHD. This is also
due to the amount of substitution solutions needed to ob-
tain an adequate clearance (at least 15 L/day of filtrate are
recommended)6,55.
Influence of CRRT on Outcome of ARF Patients
The advantages of CRRT should theoretically translate
into improved outcomes as the ultimate measure of treat-
ment efficiency. Several studies have compared CRRT with
IHD and reported a trend toward improved survival with
CRRT43,56. In a study by Bellomo et a1.43, a group of 24
CAVHDF/CVVHDF patients with a medium Apache II
score of 24 to 29 demonstrated a significantly lower mor-
tality rate of 53% compared with the IHD group (87%).
These results were confirmed in a subsequent analysis in
234 ICU patients, in which continuously treated patients
with Apache II score of 19 to 29 again had a significantly
lower mortality rate than ARF patients treated with IHD
or peritoneal dialysis (PD)57. It was noticed that CRRTs
were started earlier and at lower mean plasma creatinine and
urea concentrations, which might have contributed to the
improved outcome56. Kresse et al.58 compared demograph-
ics, severity, course, and prognosis of ARF during 36
months (period 1: 1991 to 1993; 128 patients) and 18
months (period 2: 1994 through 1995; 141 patients). There
were no significant differences in patient demographics or
etiology of ARF, but the therapeutic approach was differ-
ent. During period 2, RRT was strated at earlier stages of
renal failure, and in comparison with period 1, the mortal-
ity rate was reduced from 78.9% to 59.6% (P<0.001 ). The
mortality in ARF patients treated with CRRT was in pe-
riods 1 and 2 higher than the mortality in patients treated
with IHD, but these results are biased by a preferred use
of CRRT in severely ill patients with unstable circulatory
system. These data suggest that the early onset of RRT
reduces the mortality rate of ICU ARF patients58. Mehta
et al.59 reporte on the results of a randomized, controlled
multicenter trial of 166 ARF patients. Patients treated with
CRRT had a significantly higher Apache II score (25.3 vs
20.6), and significantly higher mortality rate (59.5% vs
41.5%) compared with ARF patients treated with IHD59.
CRRTs are predominantly used in hemodynamically un-
stable patients with higher Apache II score who would not
tolerate IHD, and conversely, IHD is primarily performed
in hemodynamically more stable patients with less compli-
cated ARF, who have a much better prognosis. An analy-
sis of such different patient populations where mortality is
more dependent on the underlying disease than on ARF
per se, will inevitably fail to show any survival benefits of
different renal replacement therapies. Further evaluations
are ongoing to gain deeper insights into the influence of
renal replacement modality on ARF patient outcome.
CRRT Costs
Three recent studies provide evidence for the true cost
differences between CRRT and IHD. Silvester and
Bihari60 compared CRRT and IHD and demonstrated that
weekly costs of CRRT were approximately 1,213 USD
(9,097.50 HRK), whereas IHD costs were l,136 USD
(8,520 HRK). It can be seen that the costs of the two dif-
ferent methods at Guy’s Hospital are very close, with the
IHD being only by 6.3% cheaper60. Another recent trial
compared weekly costs of CRRT and IHD and found
CRRT cost of 1,915 USD (14,362.50 HRK) and IHD 867
USD (6,502.50 HRK)61. Cost per survivor was 2,872 USD
(21,540 HRK) for CRRT, and 1,300 USD (9,750 HRK)
for IHD61. Mehta et a1.62 recently completed a prospec-
tive randomized multi-institutional trial that enrolled 166
ICU ARF patients treated with CRRT or IHD. There was
no mortality advantage demonstrated by either therapy, and
25% of the patients crossed over during the trial. Signifi-
cant factors that were demonstrated with this trial included
achieving caloric and protein targets more often and bet-
ter positive fluid balance with CRRT. When comparing
direct costs for the randomized patients in the San Diego
study, IHD led to an aggregate cost of 3,077 USD
(23,077.50 HRK), and CRRT 3,946 USD (29,595 HRK)
for 8.4 and 7.9 treatments, respectively. The cost analysis
for labor and materials per treatment showed that the la-
bor costs were not different between these two therapies,
but there was a significant difference in material costs, with
CRRT being 338 USD (2,535 HRK) and IHD 66 USD
(495 HRK) per treatment. This study would suggest that
cost differences are real and approximate 250 to 300 USD
(1,875 to 2,250 HRK) per treatment62.
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Saæetak
KONTINUIRANA NADOKNADA BUBREÆNE FUNKCIJE
P. Kes
Akutno zatajenje bubrega (AZB) danas se najËe¹Êe javlja u sklopu sloæenih sindroma poput sepse i/ili vi¹estrukog zatajenja
organa. Napredak na podruËju hemodijalize doveo je do usporednog razvoja novih tehnika lijeËenja koje se temelje na
kontinuiranoj nadoknadi bubreæne funkcije. Metode kontinuirane nadoknade bubreæne funcije razlikuju se s obzirom na
krvoæilni pristup, uporabu difuzije ili konvekcije u Ëi¹Êenju krvi (ili kombinaciju obiju metoda), kao i prema mjestu u
izvantjelesnom optoku na kojem se dodaje nadoknadna tekuÊina. Metode kontinuirane nadoknade bubreæne funkcije znaËajno
su olak¹ale lijeËenje te¹kih bolesnika s AZB koji imaju nestabilan srËanoæilni sustav, suvi¹ak tekuÊine, nalaze se u stanju
pojaËanog katabolizma, imaju edem mozga ili sindrom iscrpljenih pluÊa u odraslih, laktacidozu, sepsu ili sistemski upalni
odgovor, nagnjeËenja, zatajenje srca ili srËanopluÊno premo¹tenje. Postupci kontinuiranog lijeËenja AZB imaju niz prednosti
koje ukljuËuju pobolj¹anu hemodinamsku stabilnost, uravnoteæenje tekuÊine u organizmu, postupno odstranjenje ureje, uklanjanje
posrednika sepse i moguÊnost neograniËene parenteralne prehrane. Medu najznaËajnije nedostatke i do danas nerije¹ene
probleme metoda za kontinuirano lijeËenje AZB spadaju potreba za trajnom primjenom antikoagulansa, znaËajni gubitci
aminokiselina, vitamina, oligominerala, kalija, fosfata i nekih lijekova, kao i vrlo ograniËena pokretljivost bolesnika. Prednosti
metoda kontinuiranog lijeËenja AZB mogle bi teorijski rezultirati boljim ishodom lijeËenja vrlo te¹kih bolesnika s AZB, ali
su rezultati istraæivanja na tome podruËju jo¹ uvijek neujednaËeni bez obzira na ohrabrujuÊe rezultate nekih kliniËkih ispitivanja.
KljuËne rijeËi: Bubreæno zatajenje, akutno; Bubreæno zatajenje, akutno - terapija; Nadoknada bubreæne funkcije; Nadoknada
bubreæne funkcije - ekonomiËnost
